EKSO
Ekso Bionics Holdings Inc
$
4.670
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
4.860
Open
4.860
VWAP
4.66
Vol
63.75K
Mkt Cap
15.84M
Low
4.500
Amount
297.18K
EV/EBITDA(TTM)
--
Total Shares
18.17M
EV
17.99M
EV/OCF(TTM)
--
P/S(TTM)
0.67
Ekso Bionics Holdings, Inc. designs, develops, and markets exoskeleton products. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. It operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. It enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q2
FY2026Q1
FY2025Q4
4.40M
+113.9%
-0.240
-80.65%
4.75M
+40.74%
-0.295
-83.61%
5.38M
+5.61%
-0.515
-75.48%
Estimates Revision
The market is revising No Change the revenue expectations for Ekso Bionics Holdings, Inc. (EKSO) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 56.19%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+56.19%
In Past 3 Month
1 Analyst Rating
-14.35% Downside
Wall Street analysts forecast EKSO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EKSO is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
-14.35% Downside
Current: 4.670
Low
4.00
Averages
4.00
High
4.00
-14.35% Downside
Current: 4.670
Low
4.00
Averages
4.00
High
4.00
Lake Street
Buy
downgrade
$15
2025-07-29
Reason
Lake Street
Price Target
$15
2025-07-29
downgrade
Buy
Reason
Lake Street lowered the firm's price target on Ekso Bionics to $9.50 from $15 and keeps a Buy rating on the shares. Q2 revenue fell "well below" the firm's expectations, attributable to the company's Enterprise Health business. While the firm does not believe investors "should become overly concerned with the company's Q2 results," it recognizes improvements "may not be readily evident prior to the company requiring additional funds."
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$9
2025-03-04
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$9
2025-03-04
Reiterates
Strong Buy
Reason
Lake Street
Ben Haynor
Strong Buy
Maintains
$2 → $1
2025-03-04
Reason
Lake Street
Ben Haynor
Price Target
$2 → $1
2025-03-04
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Strong Buy
Reiterates
$9
2025-01-14
Reason
HC Wainwright & Co.
Swayampakula Ramakanth
Price Target
$9
2025-01-14
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Ekso Bionics Holdings Inc (EKSO.O) is -3.93, compared to its 5-year average forward P/E of -3.09. For a more detailed relative valuation and DCF analysis to assess Ekso Bionics Holdings Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-3.09
Current PE
-3.93
Overvalued PE
-1.32
Undervalued PE
-4.85
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-0.54
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1.87
Undervalued EV/EBITDA
-2.95
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
2.15
Current PS
4.85
Overvalued PS
4.36
Undervalued PS
-0.06
Financials
Annual
Quarterly
FY2025Q3
YoY :
+2.37%
4.23M
Total Revenue
FY2025Q3
YoY :
-46.87%
-1.40M
Operating Profit
FY2025Q3
YoY :
-31.42%
-1.42M
Net Income after Tax
FY2025Q3
YoY :
-64.71%
-0.54
EPS - Diluted
FY2025Q3
YoY :
-9.28%
-2.07M
Free Cash Flow
FY2025Q3
YoY :
+12.71%
60.30
Gross Profit Margin - %
FY2025Q3
YoY :
-33.00%
-33.62
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
EKSO News & Events
Events Timeline
2025-10-29 (ET)
2025-10-29
08:05:26
Ekso Bionics sets price for 769,490 shares at $4.81 in a registered direct offering
2025-10-28 (ET)
2025-10-28
16:42:33
Ekso Bionics Announces Q3 Earnings Per Share of 54 Cents, Below Consensus Estimate of 96 Cents
2025-07-28 (ET)
2025-07-28
16:23:01
Ekso Bionics reports Q2 EPS ($1.24) vs. ($1.99) last year
Sign Up For More Events
Sign Up For More Events
News
4.0
09-26NASDAQ.COMEkso Bionics (EKSO) Receives Upgrade to Buy: Key Information You Need to Know
2.0
09-19NASDAQ.COMEmerging Growth Stocks Experience Significant Gains in After-Hours Trading
9.5
09-11BenzingaOxford Industries Shares Rise Approximately 15%; Check Out 20 Stocks Making Moves in Premarket Trading
Sign Up For More News
People Also Watch
PRPH
Prophase Labs Inc
0.283
USD
+1.07%
EDUC
Educational Development Corp
1.350
USD
0.00%
NCI
Neo-Concept International Group Holdings Ltd
1.055
USD
-12.81%
AQMS
Aqua Metals Inc
7.350
USD
+11.20%
CWD
CaliberCos Inc
2.950
USD
-1.01%
TKLF
Tokyo Lifestyle Co Ltd
3.090
USD
+0.65%
PHGE
Biomx Inc
0.403
USD
+3.33%
BOF
BranchOut Food Inc
2.970
USD
+1.02%
DPRO
Draganfly Inc
8.470
USD
+8.31%
FAQ
What is Ekso Bionics Holdings Inc (EKSO) stock price today?
The current price of EKSO is 4.67 USD — it has decreased -3.71 % in the last trading day.
What is Ekso Bionics Holdings Inc (EKSO)'s business?
What is the price predicton of EKSO Stock?
What is Ekso Bionics Holdings Inc (EKSO)'s revenue for the last quarter?
What is Ekso Bionics Holdings Inc (EKSO)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Ekso Bionics Holdings Inc (EKSO)'s fundamentals?
How many employees does Ekso Bionics Holdings Inc (EKSO). have?